# Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/rituximab-chimeric-anti-cd20-monoclonal-antibody-therapy-for-relapsed-indolent/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Peter McLaughlin,A.J. Grillo-López,Brian K. Link,Ronald Levy,M. S. Czuczman,Michael E. Williams,Meyer R. Heyman,Isabelle Bence‐Bruckler,Christine A. White,Fernando Cabanillas,Vinay Jain,Anthony D. Ho,John Lister,Ken Wey,Diying Shen,B.K. Dallaire |
| Citations | 2,762 |
| DOI | 10.1200/jco.1998.16.8.2825 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1915689252 |
| PMID | 9704735 |
| Type | article |
| Year | 1998 |

## Paper authors

- [John Lister](https://scholariq.org/researchers/john-lister/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Paper topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.